Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Susan Ottman"'
Autor:
Robert Wesolowski, Rachel M. Layman, Amy S. Ruppert, Anissa Bingman, Bhuvaneswari Ramaswamy, Eric H. Kraut, Sarah Carothers, Maryam B. Lustberg, Susan Ottman, Ewa Mrozek, Charles L. Shapiro, Raquel E. Reinbolt, Melinda Lynn
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:1183-1190
Triple negative breast cancers (TNBC) frequently have high epidermal growth factor receptor (EGFR) expression and are sensitive to DNA-damaging agents. Improved therapies are needed for this aggressive malignancy.We performed a phase I trial of benda
Autor:
Charles L. Shapiro, Bhuvaneswari Ramaswamy, Rachel M. Layman, Ewa Mrozek, Larry J. Schaaf, Xiaobai Li, Susan Ottman
Publikováno v:
Clinical Breast Cancer. 12:151-156
Exemestane, the irreversible steroidal aromatase inhibitor, and fulvestrant, the pure estrogen antagonist, are active as single drugs in postmenopausal women with advanced hormone-responsive breast cancer. We designed a phase II study with the purpos
Autor:
Mahmoud Abdel-Rasoul, Robert Wesolowski, Katlyn Tolliver, Raquel E. Reinbolt, Erin Macrae, Bhuvaneswari Ramaswamy, Michael C. Ostrowski, Maryam B. Lustberg, Gustavo Leone, Susan Ottman, Ewa Mrozek, Charles L. Shapiro, Rachel M. Layman, James L. Chen, Cynthia Timmers
Publikováno v:
Cancer Research. 75:P2-03
Introduction: Foundation Medicine Incorporated (FMI) uses next generation sequencing (NGS) to simultaneously identify oncogenic molecular events and match targeted therapies to these alterations. We conducted a prospective study of the FMI test to de
Autor:
William E. Carson, Charles L. Shapiro, Adam Brufsky, Donn C. Young, Michael A. Caligiuri, Julie M. Roda, Peter A. Kaufman, Aruna Mani, Susan Ottman, Gini F. Fleming
Publikováno v:
Breast cancer research and treatment. 117(1)
Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed o
Autor:
Anne McVey, Mark Knapp, Taral Patel, Donn C. Young, Charles L. Shapiro, Mark E. Thompson, Ewa Mrozek, Susan Ottman, Shannon Puhalla, Nancy J. Merriman, Timothy David Moore, James F. Maher, Kari Kendra
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(10)
Purpose An anthracycline-based combination followed by, or combined with, a taxane is the sequence used in most adjuvant chemotherapy regimens. We hypothesized that administering the taxane before the anthracycline combination would be associated wit
Autor:
Robert Wesolowski, Jun Zhang, Andrea Camp, Michael V. Knopp, Maryam B. Lustberg, Susan Ottman, Eleni Andreopoulou, Meng Zhao, Jeffrey J. Chalmers, Miguel A. Villalona-Calero, Bhuvaneswari Ramaswamy, Charles L. Shapiro, Ewa Mrozek, Nathan Hall, Rachel M. Layman, Erin Macrae Macrae, Susan Geyer, Michael R. Grever, Katharina Schregel
Publikováno v:
Journal of Clinical Oncology. 32:1074-1074
1074 Background: Poly(ADP-ribose) polymerase (PARPi) inhibitors have shown activity in BRCA mutant and triple negative breast cancers (TNBC). The ideal dose and schedule of C and oral PARPi V is no...
Autor:
Robert Wesolowski, Jeffrey J. Chalmers, Jun Zhang, Ewa Mrozek, Michael V. Knopp, Susan Geyer, Andrea Camp, Katharina Schregel, Maryam B. Lustberg, Susan Ottman, Miguel A. Villalona-Calero, Bhuvaneswari Ramaswamy, Rachel M. Layman, Charles L. Shapiro, Erin M. Olson, Nathan Hall, Michael R. Grever
Publikováno v:
Journal of Clinical Oncology. 31:1023-1023
1023 Background: We are currently conducting a phase I trial of PARP inhibitor, V on an intermittent (7 or 14 day) or continuous (21 day) schedule in combination with C in patients (pts) with advanced breast cancer. We are using FLT PET/CT sequential
Autor:
Charles L. Shapiro, R. Jiminez, Susan Ottman, Stephen P. Povoski, Robert W. Brueggemeier, Donna R. Shiels, J. Dehart, L. Xiaobia
Publikováno v:
Journal of Clinical Oncology. 25:11056-11056
11056 Background: Aromatase [CYP19] activity and expression is increased by prostaglandin E2, thus providing a rational for combining the COX-2 inhibitor, CELE, with an aromatase inhibitor. To evaluate the effects of these drugs on proliferation and
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.